Login with your work email address to view charts. No credit card required.
| Art Unit: | 1644 — Drug, bio-affecting and body treating compositions |
|---|---|
| Group: | 1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology |
| Classes: |
424 — Drug, bio-affecting and body treating compositions 435 — Chemistry: molecular biology and microbiology 530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof 514 — Drug, bio-affecting and body treating compositions 536 — Organic compounds -- part of the class 532-570 series 436 — Chemistry: analytical and immunological testing |
| Phone: | (571) 272-9033 |
| Email: | zachary.skelding@uspto.gov |
| Location: | VA 22314 |
| Title: | Pat Examnr Biolgy |
| Service: | 20 years |
| Grade: | GS-14 |
| 3-Year Grant rate: | 62% over 364 cases |
|---|---|
| Difficulty: | Harder |
| Difficulty Percentile: | 71st
|
With Examiner Skelding, you have a 62% chance of getting an issued patent by 3 years after the first office action. Examiner Skelding is a harder examiner and in the 71st percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Skelding, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Skelding's grant rate is higher than that of Art Unit 1644 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Skelding | 1.2 |
| Art Unit 1644 | 1.6 |
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Subscribe to Premium Examiner Statistics for unlimited access to our examiner statistics.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.